Immuno-Biological Laboratories Co., Ltd. (4570) AI Stock Analysis

• Market Cap: ¥13.34B
• Dividend Yield: N/A
• Average Volume (3M): 23.51K
• Price to Earnings (P/E): 41.4
• Beta (1Y): 0.97
• Revenue Growth: 12.91%
• EPS Growth: 37.96%
• Country: JP
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 11.44
• Shares Outstanding: 9,314,590
• 10 Day Avg. Volume: 28,690
• 30 Day Avg. Volume: 23,506
• PEG Ratio: 0.54
• Price to Book (P/B): 2.95
• Price to Sales (P/S): 4.61
• P/FCF Ratio: 36.10
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 72 Outperform
• Price Target: ¥1,626.00 ▲(15.81% Upside)
• Action: Upgraded Date: 12/31/25
• Date: Action: Upgraded 12/31/25

The score is driven primarily by improved financial performance (strong margins, profitability turnaround, low leverage) and a clear positive price trend with supportive momentum. These strengths are tempered by a rich valuation (P/E 55.3) and no dividend yield data.

Positive Factors

Robust margins & profitability

Sustained high gross (64.8%) and improved net margins (25.7%) indicate durable pricing power and efficient cost structure tied to reagent/kit sales. Strong margins support reinvestment in R&D, funding of new assays, and resilience through demand cycles, enhancing long-term cash generation.

Negative Factors

Modest revenue growth

Single-digit top-line growth (~8.8%) implies limited organic expansion and could constrain the pace of portfolio diversification or large-scale R&D investment. Over months this may limit the company’s ability to scale commercial operations versus faster-growing peers in biotech diagnostics markets.

Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model

Company Description

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; a...

Read more

Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; a...

How the Company Makes Money

The company primarily makes money by selling life-science and diagnostic products and by providing related services. Key revenue streams include: (1) Product sales to research and clinical/diagnostic customers, such as antibodies, ELISA kits, and ...

Read more

The company primarily makes money by selling life-science and diagnostic products and by providing related services. Key revenue streams include: (1) Product sales to research and clinical/diagnostic customers, such as antibodies, ELISA kits, and ...

Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	951.89M	969.53M	816.70M	794.62M	647.58M	602.75M
Gross Profit	632.07M	628.34M	517.29M	526.71M	376.70M	346.86M
EBITDA	225.22M	226.55M	128.11M	-332.00M	-249.50M	-309.88M
Net Income	258.63M	249.05M	186.69M	-289.73M	-258.77M	-318.83M
Balance Sheet
Total Assets	1.92B	1.85B	1.62B	1.43B	1.71B	1.84B
Cash, Cash Equivalents and Short-Term Investments	903.75M	825.73M	734.14M	614.16M	508.35M	604.19M
Total Debt	196.94M	204.23M	235.98M	234.99M	234.00M	90.00M
Total Liabilities	343.43M	332.03M	354.25M	355.72M	336.99M	208.76M
Stockholders Equity	1.58B	1.51B	1.27B	1.08B	1.37B	1.63B
Cash Flow
Free Cash Flow	0.00	123.83M	115.11M	26.46M	-93.20M	-207.60M
Operating Cash Flow	0.00	183.50M	133.78M	26.46M	-93.20M	-194.15M
Investing Cash Flow	0.00	-53.66M	-24.50M	30.04M	-155.63M	-17.23M
Financing Cash Flow	0.00	-31.75M	991.00K	991.00K	144.00M	-216.00M

Immuno-Biological Laboratories Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1404.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Neutral. The current price of 1404 is below the 20-day moving average (MA) of 1418.07, below the 50-day MA of 1521.72, and above the 200-day MA of 1034.69, indicating a neutral trend. The MACD of -15.60 indicates Negative momentum. The RSI at 50.53 is Neutral, neither overbought nor oversold. The STOCH value of 81.50 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4570.

Immuno-Biological Laboratories Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4570	72 Outperform	¥13.34B	41.40	―	―	12.91%	37.96%
4978	56 Neutral	¥17.03B	120.78	―	―	1.24%	-33.41%
4974	52 Neutral	¥137.39B	-8.84	―	2.18%	-0.16%	-802.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
7774	51 Neutral	¥24.20B	-34.16	―	―	-5.65%	-469.19%
7776	49 Neutral	¥11.31B	-8.14	―	―	-42.49%	-2.37%
4599	45 Neutral	¥19.06B	-11.30	―	―	―	11.34%